These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

986 related items for PubMed ID: 10360171

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Seeking ligands for lonely orphan receptors.
    Gustafsson JA.
    Science; 1999 May 21; 284(5418):1285-6. PubMed ID: 10383308
    [No Abstract] [Full Text] [Related]

  • 23. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis.
    Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, Roth ME, Maloney PR, Willson TM, Kliewer SA.
    Mol Cell; 2000 Sep 21; 6(3):517-26. PubMed ID: 11030332
    [Abstract] [Full Text] [Related]

  • 24. A natural product that lowers cholesterol as an antagonist ligand for FXR.
    Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD.
    Science; 2002 May 31; 296(5573):1703-6. PubMed ID: 11988537
    [Abstract] [Full Text] [Related]

  • 25. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors.
    Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, Mangelsdorf DJ.
    Mol Cell; 2000 Sep 31; 6(3):507-15. PubMed ID: 11030331
    [Abstract] [Full Text] [Related]

  • 26. FXR, a therapeutic target for bile acid and lipid disorders.
    Westin S, Heyman RA, Martin R.
    Mini Rev Med Chem; 2005 Aug 31; 5(8):719-27. PubMed ID: 16101408
    [Abstract] [Full Text] [Related]

  • 27. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis.
    Edwards PA, Kast HR, Anisfeld AM.
    J Lipid Res; 2002 Jan 31; 43(1):2-12. PubMed ID: 11792716
    [Abstract] [Full Text] [Related]

  • 28. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.
    Pellicciari R, Costantino G, Camaioni E, Sadeghpour BM, Entrena A, Willson TM, Fiorucci S, Clerici C, Gioiello A.
    J Med Chem; 2004 Aug 26; 47(18):4559-69. PubMed ID: 15317466
    [Abstract] [Full Text] [Related]

  • 29. Antagonism of the actions of peroxisome proliferator-activated receptor-alpha by bile acids.
    Sinal CJ, Yoon M, Gonzalez FJ.
    J Biol Chem; 2001 Dec 14; 276(50):47154-62. PubMed ID: 11606578
    [Abstract] [Full Text] [Related]

  • 30. Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064.
    Martínez-Fernández P, Hierro L, Jara P, Alvarez L.
    Am J Physiol Gastrointest Liver Physiol; 2009 May 14; 296(5):G1119-29. PubMed ID: 19228886
    [Abstract] [Full Text] [Related]

  • 31. Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity.
    Gineste R, Sirvent A, Paumelle R, Helleboid S, Aquilina A, Darteil R, Hum DW, Fruchart JC, Staels B.
    Mol Endocrinol; 2008 Nov 14; 22(11):2433-47. PubMed ID: 18755856
    [Abstract] [Full Text] [Related]

  • 32. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes.
    Landrier JF, Eloranta JJ, Vavricka SR, Kullak-Ublick GA.
    Am J Physiol Gastrointest Liver Physiol; 2006 Mar 14; 290(3):G476-85. PubMed ID: 16269519
    [Abstract] [Full Text] [Related]

  • 33. The novel compounds that activate farnesoid X receptor: the diversity of their effects on gene expression.
    Suzuki T, Tamehiro N, Sato Y, Kobayashi T, Ishii-Watabe A, Shinozaki Y, Nishimaki-Mogami T, Hashimoto T, Asakawa Y, Inoue K, Ohno Y, Yamaguchi T, Kawanishi T.
    J Pharmacol Sci; 2008 Jul 14; 107(3):285-94. PubMed ID: 18603830
    [Abstract] [Full Text] [Related]

  • 34. Hypoxia downregulates farnesoid X receptor via a hypoxia-inducible factor-independent but p38 mitogen-activated protein kinase-dependent pathway.
    Fujino T, Murakami K, Ozawa I, Minegishi Y, Kashimura R, Akita T, Saitou S, Atsumi T, Sato T, Ando K, Hara S, Kikugawa K, Hayakawa M.
    FEBS J; 2009 Mar 14; 276(5):1319-32. PubMed ID: 19187229
    [Abstract] [Full Text] [Related]

  • 35. The nuclear hormone receptor farnesoid X receptor (FXR) is activated by androsterone.
    Wang S, Lai K, Moy FJ, Bhat A, Hartman HB, Evans MJ.
    Endocrinology; 2006 Sep 14; 147(9):4025-33. PubMed ID: 16675527
    [Abstract] [Full Text] [Related]

  • 36. Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression.
    Jung D, Kullak-Ublick GA.
    Hepatology; 2003 Mar 14; 37(3):622-31. PubMed ID: 12601360
    [Abstract] [Full Text] [Related]

  • 37. Binding mode of 6ECDCA, a potent bile acid agonist of the farnesoid X receptor (FXR).
    Costantino G, Macchiarulo A, Entrena-Guadix A, Camaioni E, Pellicciari R.
    Bioorg Med Chem Lett; 2003 Jun 02; 13(11):1865-8. PubMed ID: 12749886
    [Abstract] [Full Text] [Related]

  • 38. Nuclear receptor ligands and cofactor recruitment: is there a coactivator "on deck"?
    Nettles KW, Greene GL.
    Mol Cell; 2003 Apr 02; 11(4):850-1. PubMed ID: 12718871
    [Abstract] [Full Text] [Related]

  • 39. The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases.
    Niesor EJ, Flach J, Lopes-Antoni I, Perez A, Bentzen CL.
    Curr Pharm Des; 2001 Mar 02; 7(4):231-59. PubMed ID: 11254888
    [Abstract] [Full Text] [Related]

  • 40. FXR, a target for different diseases.
    Wang YD, Chen WD, Huang W.
    Histol Histopathol; 2008 May 02; 23(5):621-7. PubMed ID: 18283647
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 50.